Patent ID: 8690933

Claim:
A method of reducing effects of restless legs syndrome in a subject, the method comprising: identifying, on the subject, a body region of the subject affected by restless legs syndrome; placing an emitter unit in direct contact with skin of the body region, wherein the emitter unit comprises at least one emitter that emits near-infrared light at a wavelength of 890 nanometers, and wherein the emitter unit comprises a pad to deliver, directly to the skin of the body region of the subject, an epicutaneous drug for treating restless legs syndrome; and activating the at least one emitter to emit an effective amount of near-infrared light for a treatment duration of at least thirty minutes to induce generation of nitric oxide from at least one of hemoglobin and the endothelium within the body region, wherein the near-infrared light penetrates into tissue of the body region deeper than visible light would penetrate.